Hui-Sheng Chen

Company snapshot

Hui-Sheng Chen is a pharma organization headquartered in CN. Primary therapeutic focus areas include Ischemic Stroke. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Hui-Sheng Chen. Not investment advice.

• What is Hui-Sheng Chen?

  Hui-Sheng Chen is a pharma organization headquartered in CN. Primary therapeutic focus areas include Ischemic Stroke. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.

• Is Hui-Sheng Chen publicly traded?

  Hui-Sheng Chen appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Hui-Sheng Chen develop or market?

  We link 3 drug profile(s) where Hui-Sheng Chen is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/hui-sheng-chen#company-drugs.

• What are the latest developments for Hui-Sheng Chen?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Hui-Sheng Chen focus on?

  Hui-Sheng Chen focuses on Ischemic Stroke based on our analysis of their pipeline programs and drug development activities.